Statins and congestive heart failure

Current Atherosclerosis Reports

Volumn 10, Issue 5, 2008, Pages 369-376

  Martin, Jennifer ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA BASE; DRUG MECHANISM; HUMAN; LOW DRUG DOSE; MORBIDITY; MYOPATHY; POST HOC ANALYSIS; REVIEW; SURVIVAL; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECT; HEART FAILURE; PHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; TREATMENT OUTCOME;

EID: 55449111324     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0058-3     Document Type: Review

References (68)

1. Scandinavian Simvastatin Survival Study Investigators: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389.
2. Group HPSC: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002, 360:7-22.
3. McGirt M, Perler B, Brooke B, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005, 42:829-836.
4. Yasuda H, Yuen P, Hu X, et al.: Simvastatin improves sepsisinduced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006 Mar 22 (Epub ahead of print).
5. Mason NA, Bailie GR, Satayathum S, et al.: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005, 45:119-126.
6. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000, 356:930-933.
7. Kronmal R: Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med 1993, 153:1065-1073.
8. Onder G, Landi F, Volpato S, et al.: Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 2003, 115:265-271.
9. Rauchhaus M, Clark A, Doehner W, et al.: The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003, 42:1933-1940.
10. Martin J, Krum H: Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class. Are they clinically relevant? Drug Safety 2003, 26:13-21.
11. Cohn JN, Johnson GC, Shabetai R: Mechanistic data from the VA Cooperative studies: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993, 86(Suppl VI):VI-5-VI-16.
12. Floras J: Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993, 4(Suppl A):72A-84A.
13. Martin J, Denver R, Bailey M, et al.: In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodelling. Clin Exp Pharmacol Physiol 2005, 32:697-701.
14. Oi S, Haneda T, Osaki J, et al.: Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999, 376:139-148.
15. Takemoto M: HMG-CoA reductase inhibitors attenuate angiotensin-II induced cardiac hypertrophy. Circulation 2000, 102(SupplII): II-133.
16. Bauersachs J, Galuppo P, Fracarollo D, et al.: Improvement of left ventricular remodelling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001, 104:982-987.
17. Kureishi Y, Luo Z, Shoijima I, et al.: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
18. Vaughan C: Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082.
19. Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
20. Hasegawa H, Yamamoto R, Takano H, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003, 35:953-960.
21. Kang P, Izumo S: ApoptoAis and heart failure: a critical review of the literature. Circ Res 2000, 86:1107-1113.
22. Feron O, Dessy C, Desager J, et al.: Hydroxy-methylglutarylcoenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
23. Vergnani L, Hatrik S, Ricci F, et al.: Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: Key role of 1 arginine availability. Circulation 2000, 101:1261-1266.
24. Nahrendorf M, Hu K, Hiller KH, et al.: Impact of hydroxymethylglutaryl conenzyme A reductase inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2002, 40:1695-1700.
25. Yokota T, Utsunomiya K, Murakawa Y, et al.: Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int 1999, 71(Suppl):S178-S181.
26. Vrtovsnik F, Couette S, Prie D, et al.: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 1997, 52:1016-1027.
27. Negre-Aminou P, van Vliet AK, van Erck M, et al.: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997, 1345:259-268.
28. Koch G, Benz C, Schmidt G, et al.: Role of Rho proteins in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther 1997, 283:901-909.
29. Riessen R, Axel DI, Fenchel M, et al.: Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. Basic Res Cardiol 1999, 94:322-332.
30. Spinale F, Coker M, Bond B, et al.: Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res 2000, 46:225-238.
31. Wright R, Bybee K, Miller W, et al.: Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. Int J Cardiol 2006, 108:314-319.
32. Scirica B, Morrow D, Cannon C, et al.: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 64:2326-2331.
33. Chen M, Lam A, Abraham J, et al.: CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: A potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32:1805-1819.
34. Ruperez M, Lorenzo O, Blanco-Colio L, et al.: Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003, 108:1499-1505.
35. Martin J, Connelly K, Boyle A, et al.: Effect of HMG-CoA reductase inhibitors on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction. J Mol Cell Cardiol 2008 (in press).
36. Bauerle P, Henkel T: Function and activation of NF-kB in the immune system. Annu Rev Immunol 1995, 12:141-179.
37. Okamoto T, Yamagishi S, Inagaki Y, et al.: Angiogenesis is induced by advanced glycation end products and its prevention by cerivistatin. FASEB J 2002, 16:1928-1930.
38. Ortego M, Bustos C, Hernandez-Presa MA, et al.: Atorvastatin reduces NF-KB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253-261.
39. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
40. Kjekshus J, Apetrei E, Barrios R, et al.: Rosuvastatin in older patients with systolic heart failure (CORONA). N Engl J Med 2007, 357:2248-2261
41. Folkeringa R, Van Kraaij D, Tieleman R, et al.: Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Failure 2006, 12:134-138.
42. Horwich T, MacLellan W, Fonarow G: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004, 43:642-648.
43. Fukuta H, Sane D, Brucks S, et al.: Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report. Circulation 2005, 112:357-363.
44. Go A, Lee W, Yang J, et al.: Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296: 2105-2111
45. Anker S, Clark A, Winkler R, et al.: Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int J Cardiol 2006, 112:234-242.
46. Krum H, Latini R, Maggioni A, et al.: Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007, 119:48-53
47. Ray J, Gong Y, Sykora K, et al.: Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165:62-67.
48. Foody J, Shah R, Galusha D, et al.: Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006, 113:1086-1092.
49. Martin J, Krum H: Statins and clinical outcomes in heart failure. Clin Sci 2007, 113:119-127.
50. de Lorgeril, M, Salen P, Bontemps L, et al.: Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. J Cardiovasc Pharmacol 1999, 33:473-478.
51. Segal R, Pitt B, Poole-Wilson PA, et al.: Effects of HMG-CoA reductase inhibitors (statins) in patients with heart failure. Eur J Heart Failure 2000, 2(Suppl 2): 96.
52. Stumpf C, Lehner C, Yilmaz A, et al.: Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci 2003, 105:45-50.
53. Hognestad A, Dickstein K, Myhre E, et al.: Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after myocardial infarction associated with heart failure. Am J Cardiol 2004, 93:603-606.
54. Joynt K, Gattis W, Hasselblad V, et al.: Effect of angiotensin-converting enzyme inhibitors, b blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004, 93:783-785.
55. Mozaffarian D, Nye R, Levy W: Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004, 93:1124-1129.
56. Ezekowitz J, McAlister F, Humphries K, et al.: The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004, 44:1587-1592.
57. Rosolova H, Cech J, Simon J, et al.: Short to long term mortality of patients hospitalised with heart failure in the Czech Republic: A report from the EuroHeart Failure Survey. Eur J Heart Failure 2005, 7:780-783.
58. Sola S, Mir M, Rajagopalan S, et al.: Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Failure 2005, 11:607-612.
59. Krum H, Bailey M, Meyer W, et al.: Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II. Cardiology 2006, 8:28-34.
60. Sacks F, Pfeffer M, Moye L, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
61. Strey C, Young J, Molyneux S, et al.: Endotheliumameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005, 179:201-206
62. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
63. Tousoulis D: StatinsBin heart failure: beyond the lipid lowering effect. Int J Cardiol 2007, 115:144-150.
64. Hong YJ, Jeong MH, Hyun DW, et al.: Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005, 95:619-622.
65. Landmesser U, Bahlmann F, Mueller M, et al.: Simvastatin versus ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005, 111:2356-2363.
66. Bleske B, Nicklas J, Bard R, et al.: Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischaemic cardiomyopathy and average low density lipoprotein level. J Am Coll Cardiol 2006, 47: 338-341.
67. Sola S, Mir M, Lerakis S, et al.: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in non-ischaemic heart failure. J Am Coll Cardiol 2006, 47: 332-337.
68. Khush K, Waters D, Bittner V, et al.: Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007, 115: 576-583.